Blair William & Co. IL Cuts Stock Position in Encompass Health Co. (NYSE:EHC)

Blair William & Co. IL decreased its position in Encompass Health Co. (NYSE:EHC - Free Report) by 5.9% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 212,018 shares of the company's stock after selling 13,280 shares during the period. Blair William & Co. IL owned about 0.21% of Encompass Health worth $19,580,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. TD Private Client Wealth LLC lifted its stake in Encompass Health by 2,870.0% in the third quarter. TD Private Client Wealth LLC now owns 7,336 shares of the company's stock worth $709,000 after acquiring an additional 7,089 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Encompass Health by 0.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 644,764 shares of the company's stock worth $59,544,000 after purchasing an additional 4,345 shares during the period. Geode Capital Management LLC boosted its stake in shares of Encompass Health by 1.2% during the 3rd quarter. Geode Capital Management LLC now owns 1,673,610 shares of the company's stock valued at $161,781,000 after purchasing an additional 20,547 shares in the last quarter. Central Pacific Bank Trust Division increased its position in shares of Encompass Health by 15.1% during the fourth quarter. Central Pacific Bank Trust Division now owns 3,195 shares of the company's stock valued at $295,000 after buying an additional 418 shares during the period. Finally, Merit Financial Group LLC bought a new position in Encompass Health in the fourth quarter worth about $374,000. 97.25% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Encompass Health Stock Performance

Shares of Encompass Health stock traded up $0.82 during trading on Wednesday, hitting $102.10. 136,023 shares of the company's stock traded hands, compared to its average volume of 643,937. Encompass Health Co. has a 1 year low of $78.53 and a 1 year high of $104.55. The business has a 50-day simple moving average of $98.92 and a 200-day simple moving average of $97.58. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.05 and a quick ratio of 1.04. The stock has a market capitalization of $10.28 billion, a P/E ratio of 22.92, a PEG ratio of 2.31 and a beta of 0.92.

Encompass Health (NYSE:EHC - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.17 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.12. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. As a group, analysts forecast that Encompass Health Co. will post 4.8 EPS for the current year.

Encompass Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Tuesday, April 1st will be paid a $0.17 dividend. The ex-dividend date is Tuesday, April 1st. This represents a $0.68 annualized dividend and a dividend yield of 0.67%. Encompass Health's dividend payout ratio (DPR) is 15.25%.

Insider Buying and Selling

In other news, CAO Andrew L. Price sold 5,042 shares of the firm's stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $98.29, for a total value of $495,578.18. Following the transaction, the chief accounting officer now owns 69,164 shares of the company's stock, valued at $6,798,129.56. This trade represents a 6.79 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.10% of the stock is owned by insiders.

Analyst Ratings Changes

EHC has been the topic of a number of research analyst reports. StockNews.com upgraded Encompass Health from a "hold" rating to a "buy" rating in a report on Saturday, February 15th. Royal Bank of Canada reissued an "outperform" rating and set a $110.00 price objective on shares of Encompass Health in a research report on Tuesday, February 11th. KeyCorp upped their target price on shares of Encompass Health from $117.00 to $120.00 and gave the stock an "overweight" rating in a research report on Monday, February 10th. Barclays lifted their price target on shares of Encompass Health from $116.00 to $118.00 and gave the company an "overweight" rating in a research report on Friday, February 7th. Finally, William Blair reaffirmed an "outperform" rating on shares of Encompass Health in a research note on Friday, February 7th. Ten investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $107.67.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.